[Vitamins for the eyes? Risks and opportunities for physician and patient].
This article discusses the effects of dietetic measures and specialized food supplements on age-related macular degeneration (AMD) and diabetic retinopathy. The sale of products in doctors' offices is already prohibited by laws governing the medical profession. The results of the Age-Related Eye Disease Study (AREDS) concerning high doses of vitamins and zinc cannot simply be transferred to other doses and substances. Furthermore, there are health risks that have to be examined. Opportunities could arise for both doctor and patient if the AREDS formulation were granted authorization to be marketed as a medicinal product; however, a certain protective effect can be expected only for specific forms of AMD after a careful risk-benefit analysis and assessment within the statutory marketing authorization procedure for medicinal products.
Grossklaus
R
R
Bundesinstitut für Risikobewertung (BfR), Berlin, Deutschland. Rolf.Grossklaus@bfr.bund.de
Henning
K J
KJ
D003930:Diabetic Retinopathy / Q000178:diet therapy* / Q000188:drug therapy*; D019587:Dietary Supplements; D005858:Germany; D008268:Macular Degeneration / Q000178:diet therapy* / Q000188:drug therapy*; D009885:Ophthalmology / Q000331:legislation & jurisprudence*; D012307:Risk Factors; D014815:Vitamins / Q000627:therapeutic use*
D014815:Vitamins